Period changes on a GLP-1 and birth control

Your cycle is not imagining it

Periods changing on a GLP-1 comes up constantly and appears in almost no patient leaflet, so it is easy to assume you are the only one.

The best current read on it is a 2026 analysis of the FDA's adverse event reporting database, restricted to women aged 12 to 55. Semaglutide showed the broadest set of signals — heavier bleeding, bleeding between periods, clots, infrequent periods and cycles without ovulation. Tirzepatide showed signals for bleeding between periods and for clots. Liraglutide showed none¹.

Read that for what it is. A reporting database records what people and clinicians report, so a drug everyone is talking about generates more reports about everything. It cannot show cause. What it can do is confirm that this is a real pattern rather than a forum rumor, and that is worth having.

Why weight loss alone moves your cycle

There is a much less mysterious mechanism running underneath, and for many women it is the whole story. Body fat is hormonally active. Losing a lot of it changes estrogen, insulin and the signalling that decides whether you ovulate in a given month.

In practice that most often means ovulation coming back. In an uncontrolled six-month study of 96 women with polycystic-ovary-type irregular cycles and a BMI above 25, average weight fell 11.3% on semaglutide — and among the women who had not been ovulating beforehand, 52.5% were ovulating by the end². If you have spent years with unpredictable or absent periods, that is very good news for your health and possibly for your fertility.

It also means the thing nobody warns you about: you can become fertile again without any announcement. A returning cycle does not arrive with a notification.

The contraception part, exactly

This is where the two medicines genuinely differ, and where a lot of general advice gets it wrong by treating them as one class.

Tirzepatide — Mounjaro and Zepbound — has a labeled interaction with oral contraception. The Zepbound label instructs patients using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for four weeks after starting and for four weeks after every dose increase. The numbers behind that are in the same label: after a single 5 mg dose, peak concentrations of ethinyl estradiol, norgestimate and norelgestromin fell by 59%, 66% and 55%, and total exposure fell by 20%, 21% and 23%. The label also states that hormonal contraceptives which are not taken by mouth are not affected³.

The mechanism is delayed stomach emptying, and it is worst right after a dose change and settles with repeated dosing — which is exactly why the four-week windows attach to starting and to escalating rather than to the whole course. A review that compared six clinical trials found that of the six, only the tirzepatide one showed a significant reduction in oral contraceptive exposure; the five involving GLP-1 receptor agonists did not⁴.

Semaglutide does not carry that instruction. The Wegovy label does not mention contraception anywhere, and its drug-interaction section lists ethinyl estradiol and levonorgestrel among the drugs with no clinically significant pharmacokinetic difference alongside semaglutide⁵. The dedicated trial found the same: exposure to ethinyl estradiol met bioequivalence criteria, and levonorgestrel exposure was 20% higher, not lower⁶.

So: on tirzepatide, back up your pill for those four-week windows. On semaglutide, there is no such requirement. Do not let a general article about "GLP-1s and birth control" talk you out of the difference — and if you are unsure which you are on, the pen says so.

Separately, and regardless of which one: no GLP-1 is considered safe in pregnancy, which makes reliable contraception more important on these medicines, not less.

When a change is not a period

Any bleeding after menopause needs looking at, however light. In a meta-analysis of 129 studies, about 9% of women presenting with postmenopausal bleeding had endometrial cancer⁷. Bleeding between periods that is new and persistent, or bleeding after sex, is also worth an appointment rather than a wait-and-see — the other vaginal symptoms sort out alongside it.

What to do with all this

Track the dates for three cycles before deciding anything is wrong; one odd month is not a pattern. Tell your prescriber if bleeding is heavy enough to change your plans, if periods stop for three months, or if they had stopped and have restarted. And if you were relying on irregular cycles as a kind of contraception, that plan may have quietly expired.